NQO1 Antibody
Rabbit Monoclonal Antibody
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB |
---|---|
Primary Accession | P15559 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Monoclonal |
Clone Names | EPR3309 |
Calculated MW | 30868 Da |
Gene ID | 1728 |
Other Names | NAD(P)H dehydrogenase [quinone] 1, Azoreductase, DT-diaphorase, DTD, Menadione reductase, NAD(P)H:quinone oxidoreductase 1, Phylloquinone reductase, Quinone reductase 1, QR1, NQO1, DIA4, NMOR1 |
Target/Specificity | A synthetic peptide corresponding to residues on the N-terminus of human NQO1 was used as an immunogen. |
Dilution | WB~~1:1000 |
Format | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | NQO1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | NQO1 |
---|---|
Synonyms | DIA4, NMOR1 |
Function | The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. |
Cellular Location | Cytoplasm. |

Provided below are standard protocols that you may find useful for product applications.
Background
NQO1 (Quinone 1) is a flavoenzyme that catalyzes two-electron reductive metabolism and detoxification of quinones and their derivatives leading to protection of cells against redox cycling and oxidative stress (1). NQO1 is mainly cytosolic, but its nuclear presence suggests its involvement in both chemoprevention and bioactivation of DNA-damaging antitumor agents (2). NQ01 may also play a role in the bioactivation of antitumor quinones such as mitomycin C (MMC), and has been proposed to have a protective effect against cancer caused by quinones and their metabolic precursors (3-4).
References
1. Radjendirane V, et al. J Biol Chem. 273(13):7382-9, 1998
2. Winski SL, et al. Cancer Res. 62(5):1420-4, 2002
3. Traver RD, et al. Cancer Res. 52(4):797-802, 1992
4. Jaiswal AK, et al. J Biol Chem. 263(27):13572-8, 1988

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.